By admin 
CureSearch for Children’s Cancer, a leading national non-profit foundation dedicated to accelerating the development of safe and effective treatments for pediatric cancer, has officially announced the appointment of Mark Zafra to its Board of Directors. Zafra, a highly regarded executive currently serving as the Chief Procurement Officer at LiveRamp, brings a unique synthesis of high-level corporate governance expertise and a deeply personal connection to the organization’s mission. His appointment comes at a critical juncture for the foundation as it continues to expand its reach and refine its strategic approach to funding innovative clinical research that addresses the specific needs of the pediatric patient population.
The addition of Zafra to the leadership team signifies a strategic move by CureSearch to integrate sophisticated supply chain and procurement logic into its operational framework. With over two decades of experience in global strategic sourcing and organizational transformation, Zafra is expected to provide invaluable insights into resource optimization and strategic scaling. His professional background is complemented by his status as a cancer survivor, a factor that CureSearch leadership identifies as a vital asset in maintaining the organization’s focus on patient-centric outcomes.
Professional Trajectory and Strategic Expertise
Mark Zafra’s professional career is defined by a consistent record of leadership within some of the world’s most influential technology and healthcare corporations. At LiveRamp, a prominent data connectivity platform, Zafra oversees a comprehensive portfolio that includes global strategic sourcing, purchasing, travel management, and accounts payable. His role is central to the company’s operational efficiency, ensuring that global resources are utilized with maximum impact.
Prior to his tenure at LiveRamp, Zafra held senior leadership positions at Twitter, where he managed large-scale procurement initiatives during periods of rapid international expansion. His resume also includes significant roles at Allianz Fireman’s Fund, McKesson, HP, and Agilent Technologies. In these capacities, Zafra was responsible for driving innovation and efficiency across complex supply chains. This "operational excellence" mindset is particularly relevant for non-profit organizations like CureSearch, which must navigate the intricate and often expensive landscape of medical research and drug development.
By applying procurement principles—such as vendor management, cost-benefit analysis, and strategic sourcing—to the non-profit sector, Zafra is positioned to help CureSearch maximize the "return on investment" for every donor dollar. In the context of pediatric oncology, this means ensuring that funds are directed toward the most promising clinical trials and that the bureaucratic hurdles of drug development are minimized through efficient partnership management.
A Personal Milestone: Twenty Years of Survivorship
While Zafra’s professional credentials are extensive, his personal history provides the emotional and ethical foundation for his service. This year marks the 20th anniversary of Zafra’s first cancer diagnosis. His journey from patient to survivor to board member reflects a full-circle commitment to the field of oncology. This lived experience offers him a perspective that traditional corporate executives may lack: an intimate understanding of the rigors of treatment, the uncertainty of long-term prognosis, and the urgent need for therapies that are not only effective but also minimize long-term toxicity for children.
To commemorate his two decades of survivorship and to raise funds for the foundation, Zafra will participate in the CureSearch Ultimate Hike in Jackson, Wyoming. The Ultimate Hike is a signature endurance event for the organization, challenging participants to complete a rigorous trek through demanding terrain. The event serves as both a physical manifestation of the "uphill battle" faced by children with cancer and a significant fundraising vehicle for cutting-edge research. Zafra’s participation underscores his "hands-on" approach to advocacy, moving beyond the boardroom to support the cause through direct action.
The Landscape of Pediatric Cancer Research
The appointment of a new board member occurs against the backdrop of a challenging landscape for pediatric oncology. While survival rates for some forms of childhood cancer have improved significantly over the last 50 years, the field still faces systemic hurdles. According to data from the National Cancer Institute (NCI), while approximately 80% of children diagnosed with cancer survive at least five years, many of these survivors face lifelong health complications due to the toxicity of current treatments. Furthermore, pediatric cancer receives only about 4% of the federal funding allocated for cancer research by the NCI.
CureSearch for Children’s Cancer seeks to bridge this "funding gap" by focusing on the "Valley of Death"—the difficult transition period between initial laboratory discovery and the start of clinical trials. Developing drugs for children is often viewed as less commercially viable for large pharmaceutical companies due to the smaller patient population compared to adult cancers. CureSearch addresses this by providing the necessary de-risking capital and expertise to move promising pediatric treatments forward.
Zafra’s expertise in supply chain and procurement is particularly relevant here. The process of bringing a new drug to market is essentially a highly complex supply chain of data, regulatory approvals, and clinical partnerships. Strengthening these links is essential for accelerating the delivery of new therapies to the bedside.
Official Responses and Organizational Impact
The leadership at CureSearch has expressed significant optimism regarding Zafra’s appointment. Jared Brancazio, the CureSearch Board Chair, highlighted the dual nature of Zafra’s value to the organization. "Mark’s professional leadership and personal commitment to advancing cancer research make him an incredible addition to the CureSearch Board," Brancazio stated. "We’re honored to have him help guide our work and accelerate our impact."
Zafra himself emphasized the sense of duty that accompanies his new role. "It is with great enthusiasm and a deep sense of responsibility that I join CureSearch’s Board of Directors," Zafra shared. "As a survivor myself, I am a passionate advocate for advancing cancer research and am honored by the opportunity to contribute my skills and experience to a mission that matters deeply to me."
The integration of a survivor-executive into the board structure is seen by industry analysts as a best practice in non-profit governance. It ensures that the "voice of the patient" is represented at the highest levels of decision-making, while also providing the technical rigor necessary to manage a multi-million-dollar research portfolio.
Chronology of Leadership and Mission
The evolution of CureSearch’s board mirrors the broader evolution of the organization itself. Founded with a focus on supporting the Children’s Oncology Group (COG), CureSearch has transitioned over the last decade into an independent powerhouse that focuses on high-impact, private-sector-style research funding.
- Early 2000s: CureSearch establishes itself as a primary fundraiser for pediatric clinical trial networks.
- 2010s: The organization shifts its strategy toward the "Catapult" and "Acceleration" awards, designed to push specific drug candidates through the regulatory pipeline.
- 2020: The global pandemic necessitates a shift in how research is funded and how endurance events like the Ultimate Hike are managed, emphasizing the need for robust digital and logistical infrastructure.
- 2024: Mark Zafra joins the board, bringing contemporary tech-sector procurement strategies to the foundation during a period of renewed focus on international collaboration and data-driven research.
Broader Implications for the Non-Profit Sector
Zafra’s appointment is indicative of a larger trend where non-profit organizations are increasingly seeking out "functional experts" rather than just "generalist philanthropists." In an era where data privacy, global logistics, and cost-efficiency are paramount, having a Chief Procurement Officer on a board provides a level of oversight that can significantly reduce overhead and increase the percentage of funds going directly to the mission.
For CureSearch, Zafra’s presence will likely influence how the organization manages its partnerships with academic institutions and biotech firms. His experience at Twitter and LiveRamp—companies that deal with massive amounts of data and complex global networks—will be instrumental as CureSearch explores how big data and AI can be used to identify potential pediatric applications for existing adult cancer drugs.
Furthermore, Zafra’s personal story serves as a powerful tool for donor engagement. In the competitive world of charitable giving, the ability to connect a sophisticated professional background with a compelling personal narrative of survival is a potent combination. It provides donors with confidence that the organization is led by people who understand the stakes on both a financial and a human level.
Looking Forward
As Mark Zafra begins his tenure on the Board of Directors, the immediate focus will be on the upcoming Ultimate Hike in Jackson, Wyoming. This event will serve as his formal introduction to the CureSearch community of hikers, survivors, and researchers. Beyond the hike, Zafra is expected to dive into the foundation’s strategic planning for the 2025 fiscal year, where his expertise in procurement will likely be applied to optimizing the foundation’s grant-making processes.
The ultimate goal remains unchanged: ensuring that every child diagnosed with cancer has access to a treatment that is both safe and effective. With the addition of Mark Zafra, CureSearch for Children’s Cancer bolsters its ability to navigate the complex road from the laboratory to the pharmacy, bringing hope to the thousands of families affected by pediatric cancer each year. Through the synergy of professional excellence and personal passion, the foundation moves one step closer to ending the threat of childhood cancer once and for all.
